BPC-157

What is BPC-157

BPC-157 (Body Protection Compound-157) is a synthetic 15 amino acid peptide with the sequence GEPPPGKPADDAGLV. It was identified as a fragment of a larger protein found in human gastric juice. The parent protein has been studied since the 1990s, primarily by Predrag Sikiric and colleagues at the University of Zagreb, whose laboratory has produced the majority of published BPC-157 research over three decades.

As a synthetic compound, BPC-157 has no endogenous source — it does not occur naturally in the body at concentrations relevant to the published research. It is classified as a research peptide and is not an approved drug in any jurisdiction.

Angiogenesis and vascular mechanisms

The most extensively documented mechanism in BPC-157 research involves VEGF (vascular endothelial growth factor) upregulation and activation of the VEGFR2 signalling pathway. Published studies in rodent models demonstrate that BPC-157 promotes the formation of new blood vessels in injured tissue, a process called angiogenesis. New capillary formation is relevant to tissue repair research because injured tissue requires oxygen and nutrient delivery from newly formed vasculature to support cell proliferation and matrix synthesis.

BPC-157 has also been studied in the context of nitric oxide (NO) pathway modulation. Research indicates activation of endothelial nitric oxide synthase (eNOS), increasing local NO production. Nitric oxide functions as a vasodilator and plays regulatory roles in inflammation, cell survival signalling, and vascular tone. Several of the gastroprotective effects documented in BPC-157 research are attributed to NO-mediated mechanisms.

Fibroblast and connective tissue research

BPC-157 has been examined for its effects on tendon fibroblast proliferation and migration. Fibroblasts are the primary cell type responsible for synthesising collagen and extracellular matrix proteins in connective tissue. In cell culture and rodent studies, BPC-157 stimulates fibroblast activity, with researchers proposing this as a mechanism for the accelerated tendon and ligament repair observed in animal models.

Published research has also examined growth hormone receptor upregulation in healing tissue. BPC-157 appears to sensitise injured tissue to growth hormone signalling without altering systemic GH levels — a mechanistically distinct effect from direct GH administration.

Gastrointestinal research

The compound was originally characterised in the context of gastric mucosal protection. Rodent studies have examined BPC-157 in models of NSAID-induced gastric damage, alcohol-induced lesions, and stress ulcers. The gastroprotective effects appear to be mediated through the nitric oxide pathway and local prostaglandin modulation. Research has also examined effects on gut motility and intestinal anastomosis healing.

Neurological research

A separate body of research has examined BPC-157 in neurological contexts, including dopaminergic and serotonergic system modulation. Published studies report effects on dopamine and serotonin receptor expression in rodent models, with some researchers proposing applications in stress and anxiety research. The neurological mechanisms are less characterised than the vascular and connective tissue mechanisms.

Evidence quality assessment

Strong: In vitro mechanistic data and rodent model data across multiple independent laboratories for angiogenesis, fibroblast activation, and gastroprotection. The mechanistic basis is well-characterised at the molecular level.

Limited: Human controlled trial data. To date, BPC-157 has not completed Phase II or Phase III clinical trials. Evidence for human application extrapolates from animal models. The rodent-to-human translation for this compound is not established.

Researchers should note that the FDA removed BPC-157 from the list of bulk drug substances eligible for compounding in 2023-2024, citing its status as an active pharmaceutical ingredient under clinical investigation.